Charles Monier, MD
Cardiovascular Disease · Ville Platte, LANPI 1003909904
Payments from drug & device makers
Across 14 payments — averaging $24.02 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boston Scientific$119
- AbbVie$67
- Romark Laboratories, LC$32
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$31
- Medtronic$18
- Redhill Biopharma Inc.$18
- plus $50 from 3 others
What the payments were for
- Food & beverage$336100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boston Scientific | 2 | $119 |
| AbbVie | 3 | $67 |
| Romark Laboratories, LC | 2 | $32 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 2 | $31 |
| Medtronic | 1 | $18 |
| Redhill Biopharma Inc. | 1 | $18 |
| Evoke Pharma, Inc. | 1 | $18 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $17 |
| Ardelyx, Inc. | 1 | $15 |
How this compares
$336 in reported general payments places this provider in the 15th percentile of 281 cardiovascular disease providers in Louisiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EntrestoSacubitril/Valsartan | 99 | $73,798 |
| EliquisApixaban | 90 | $68,915 |
| JardianceEmpagliflozin | 93 | $52,609 |
| XareltoRivaroxaban | 50 | $40,634 |
| FarxigaDapagliflozin Propanediol | 22 | $12,500 |
| Propafenone Hcl | 47 | $2,070 |
| SotalolSotalol Hcl | 109 | $1,544 |
| Dabigatran EtexilateDabigatran Etexilate Mesylate | 12 | $1,167 |
| ClopidogrelClopidogrel Bisulfate | 182 | $897 |
| Nifedipine ErNifedipine | 46 | $836 |
| Metoprolol Succinate | 166 | $834 |
| Digoxin | 51 | $639 |
| Amlodipine Besylate | 192 | $576 |
| Carvedilol | 134 | $513 |
| Metoprolol Tartrate | 94 | $511 |
Paid to pharmacies, not to this prescriber.
Other cardiovascular disease in Ville Platte
- Ghiath MikdadiHammond$5.7M
- Marc BernsteinSlidell$2.1M
- Anil ChhabraShreveport$1.9M
- Dale PresserCovington$1.7M
- William EavesShreveport$1.6M
- Assad MouhaffelWest Monroe$1.4M
- Wenwu ZhangShreveport$1.1M
- William SmithRuston$694K
- Imran ChaudryMonroe$371K
- Keith FerdinandNew Orleans$335K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.